U.S. FDA approved Merck’s ERVEBO (Ebola Zaire Vaccine, Live) for use in children 12 months of age and older
On Aug. 3, 2023, Merck announced that the U.S. Food and Drug Administration (FDA) had approved an expanded indication for ERVEBO, which is now indicated for the prevention of disease caused by Zaire ebola virus in individuals 12 months of age and older.
The vaccine was previously approved for use in individuals 18 years of age and older.
Tags:
Source: Merck
Credit:
